A Phase 1/2, Placebo Controlled Randomized Observer Blind Dose Finding First in Humans Study to Describe the Safety Tolerability and Immunogenicity of an Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine in Healthy Older Adults

StatusActive
Effective start/end date1/03/1922/11/19

Funding

  • Pfizer Pty Ltd